Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

617 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V. Laribi K, et al. Among authors: willems l. Br J Haematol. 2019 Jul;186(1):146-149. doi: 10.1111/bjh.15718. Epub 2018 Dec 12. Br J Haematol. 2019. PMID: 30548257 Free article. No abstract available.
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L; French Innovative Leukemia Organization (FILO) CLL group. Ghez D, et al. Blood. 2018 Apr 26;131(17):1955-1959. doi: 10.1182/blood-2017-11-818286. Epub 2018 Feb 1. Blood. 2018. PMID: 29437588 Free article. Clinical Trial.
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
Quinquenel A, Fornecker LM, Letestu R, Ysebaert L, Fleury C, Lazarian G, Dilhuydy MS, Nollet D, Guieze R, Feugier P, Roos-Weil D, Willems L, Michallet AS, Delmer A, Hormigos K, Levy V, Cymbalista F, Baran-Marszak F; French Innovative Leukemia Organization (FILO) CLL Group. Quinquenel A, et al. Among authors: willems l. Blood. 2019 Aug 15;134(7):641-644. doi: 10.1182/blood.2019000854. Epub 2019 Jun 26. Blood. 2019. PMID: 31243043 Free article.
Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).
Lazarian G, Munger M, Quinquenel A, Dilhuydy MS, Veronese L, Luque Paz D, Guièze R, Ledoux-Pilon A, Paillassa J, Merabet F, Vial JP, Bidet A, Waultier Rascalou A, Broseus J, Roos-Weil D, Lavaud A, Molina L, Laribi K, Hivert B, Friedrich C, Carpentier B, Ysebaert L, Van Den Neste E, Willems L, Corby A, Poulain S, Eclache V, Maubec E, Martin A, Feugier P, Delmer A, Baran-Marszak F, Leprêtre S, Cymbalista F. Lazarian G, et al. Among authors: willems l. Am J Hematol. 2021 Sep 1;96(9):E353-E356. doi: 10.1002/ajh.26274. Epub 2021 Jul 1. Am J Hematol. 2021. PMID: 34152612 Free article. No abstract available.
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
Bagacean C, Letestu R, Al-Nawakil C, Brichler S, Lévy V, Sritharan N, Delmer A, Dartigeas C, Leblond V, Roos-Weil D, Tomowiak C, Merabet F, Béné MC, Clavert A, Chaoui D, Genet P, Guieze R, Laribi K, Drénou B, Willems L, Puppinck C, Legendre H, Troussard X, Malartre S, Cymbalista F, Michallet AS. Bagacean C, et al. Among authors: willems l. Blood Adv. 2022 Jan 11;6(1):207-211. doi: 10.1182/bloodadvances.2021006215. Blood Adv. 2022. PMID: 34844264 Free PMC article.
Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy.
Laribi K, Baugier de Materre A, Ghez D, Dartigeas C, Tomowiak C, Mahé B, Micol JB, Merabet F, Leprêtre S, Herbaux C, Ysebaert L, Le Calloch R, Willems L, Voldoire M, Roos-Weil D, Bravetti C, Touileb Y, Davi F, Nguyen-Khac F, Maloum K, Béné MC. Laribi K, et al. Among authors: willems l. Hemasphere. 2022 May 11;6(6):e716. doi: 10.1097/HS9.0000000000000716. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35747848 Free PMC article. No abstract available.
Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
Belhadj M, Burroni B, Kosmider O, Willems L, Temple M, Bertoli S, Orvain C, Dumas PY, Berthon C, Gabellier L, Marcais A, Raffoux E, Pautas C, Genthon A, Decroocq J, Birsen R, Tamburini J, Bouscary D, Contejean A. Belhadj M, et al. Among authors: willems l. Br J Haematol. 2023 Sep;202(6):e50-e53. doi: 10.1111/bjh.18961. Epub 2023 Jul 4. Br J Haematol. 2023. PMID: 37403204 No abstract available.
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
Laribi K, Poulain S, Willems L, Merabet F, Herbaux C, Roos-Weil D, Laribi de Materre I, Roussel X, Nudel M, Tricot S, Dupuis J, Le Calloch R, Bareau B, Leblond V. Laribi K, et al. Among authors: willems l. Br J Haematol. 2024 Jun;204(6):2233-2236. doi: 10.1111/bjh.19409. Epub 2024 Mar 19. Br J Haematol. 2024. PMID: 38504454
Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort.
Debureaux PE, Poulain S, Harel S, Passet M, Templé M, Friedrich C, Forgeard N, Elessa D, Plas W, Chat L, Lazarian G, Willems L, Royer B, Talbot A, Vaugeois T Dr, Theves F, Terré A, Brignier AC, Malphettes M, Krzisch D, Frenzel L, Davi F, Bravetti C, Nguyen-Khac F, Dupuis J, Cuccuini W, Bouscary D, Hermine O, Roos-Weil D, Kosmider O, Clappier E, Espéli M, Balabanian K, Arnulf B. Debureaux PE, et al. Among authors: willems l. Blood. 2024 Nov 21:blood.2024025738. doi: 10.1182/blood.2024025738. Online ahead of print. Blood. 2024. PMID: 39571148
617 results